{
    "doi": "https://doi.org/10.1182/blood.V110.11.20.20",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=905",
    "start_url_page_num": 905,
    "is_scraped": "1",
    "article_title": "Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment. ",
    "article_date": "November 16, 2007",
    "session_type": "Clinical Results - Autologous Transplantation",
    "topics": [
        "cyclophosphamide, doxorubicin, prednisone, and vincristine",
        "follicular lymphoma",
        "follow-up",
        "rituximab",
        "r-chop",
        "brachial plexus neuritis",
        "polymerase chain reaction",
        "treatment resistant disorders",
        "adverse effects",
        "chemotherapy regimen"
    ],
    "author_names": [
        "Marco Ladetto, MD",
        "Federica De Marco, MD",
        "Fabio Benedetti, MD",
        "Umberto Vitolo, MD",
        "Caterina Patti, MD",
        "Alessandro Rambaldi, MD",
        "Alessandro Pulsoni, MD",
        "Maurizio Musso, MD",
        "Anna M. Liberati, MD",
        "Attilio Olivieri, MD",
        "Andrea Gallamini, MD",
        "Enrico Pogliani, MD",
        "Delia Rota Scalabrini, MD",
        "Vincenzo Callea, MD",
        "Francesco Di Raimondo, MD",
        "Vincenzo Pavone, MD",
        "Alessandra Tucci, MD",
        "Sergio Cortelazzo, MD",
        "Alessandro Levis, MD",
        "Mario Boccadoro, MD",
        "Ignazio Majolino, MD",
        "Alessandro Pileri, MD",
        "Alessandro M. Gianni, MD",
        "Roberto Passera, PhD",
        "Paolo Corradini, MD",
        "Corrado Tarella, MD"
    ],
    "author_affiliations": [
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ],
        [
            "On Behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), And Intergruppo Italiano Linfomi (IIL), Italy"
        ]
    ],
    "first_author_latitude": "19.9030921",
    "first_author_longitude": "-75.0966509",
    "abstract_text": "Background. A randomised trial has been performed among several GITMO/IIL italian centers, comparing Rituximab-supplemented High-Dose Sequential Chemotherapy (R-HDS) and CHOP-R in high-risk FL <60 yrs. The updated results are here presented, after a median follow-up of 50 months. Patients (pts) and Methods. Eligibility was based on age-adjusted IPI >=2 (125 pts) or on the IIL score >=3 (11 pts). 136 pts were randomized (68/arm). Main clinical features were: median age 51 yrs. (22\u201359), stage III\u2013IV 98%, elevated LDH 59%, bulky disease 56%, B symptoms 47%, extranodal disease other than bone marrow (BM) 31%, PS >1 (ECOG) 60%. Both R-HDS and CHOP-R have been already described (Ladetto et al ASH 2005, Rambaldi et al Blood 2000). Cross-over was allowed for pts failing CHOP-R. Centralized minimal residual disease (MRD) analysis with the bcl-2/IgH was performed on BM samples. Analysis was intention to treat. Results. Early toxic deaths were 5 (2 in CHOP-R, 3 in R-HDS); CR rates were 61% with CHOP-R and 85% with R-HDS (p<0.001). At four years EFS and PFS are 32% and 33% for CHOP-R, and 64% and 76% for R-HDS (p<0.001). Despite a better EFS, OS is not different in the two arms (82% CHOP-R and 79% R-HDS). One fatal secondary myelodysplastic syndrome occurred in the CHOP-R arm and five (three fatal) in the R-HDS arm with a cumulative incidence at four years of 3.3% and 7.9% respectively. A stable molecular remission (MR) (achieved in 44% of CHOP-R and 80% of R-HDS pts) (p<0,001) was associated with an improved PFS (22% vs 78% at four years) (p<0,001) and proved the strongest outcome predictor for EFS and PFS by multivariate analysis (Hazard Ratio: 3.98 and 3.83, respectively). Interestingly, the PFS of PCR-negative pts was similar in the two arms, as well as that of PCR-positive pts. Of 39 patients with relapsed or refractory disease after CHOP-R 28 were crossed to R-HDS (71%). Reasons for not undergoing cross-over were: limited relapse in 4, co-morbidities in 2, refusal in 2, other causes in 3. Overall CR rate for second line treatment after CHOP-R failure was 77% (86% with R-HDS and 54% with other therapy). At a median follow-up of 30 months the three-year EFS of patients undergoing salvage R-HDS is 70%. Conclusions: In high-risk FL: a) first-line R-HDS ensures better EFS and PFS and superior molecular outcome than CHOP-R; b) pts undergoing salvage R-HDS have an excellent clinical outcome; c) the long-term OS is markedly improved compared to the pre-rituximab era, with no difference between CHOP-R and R-HDS; d) both the high efficacy as salvage treatment and the potential side effects suggest that the ideal positioning of R-HDS-like treatments is beyond first line treatment, for relapsed or refractory disease; e) a PCR-negative status is the most important prognostic factor regardless of treatment received and pts with persistent PCR-positivity might potentially be considered for specific experimental intervention."
}